-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the stage and characteristics of the disease, the incidence of brain metastases (BM) in patients with small cell lung cancer is very high, exceeding 50%.
prevention
At present, several studies have proposed several interaction mechanisms to explain neurocognitive decline, including vascular disease, oligodendrocyte reduction, central nervous system inflammation, and ecological degradation of progenitor cells in the hippocampus, which is a learning and The important structure of memory.
Blood vessel
Modern radiotherapy techniques, such as intensity modulated conformal radiotherapy and volumetric arc intensity modulated radiotherapy, allow the entire brain to be treated with standard radiation doses while maintaining low-dose exposure to the hippocampus.
In this study, patients with small cell lung cancer were randomly divided into 2 groups and received standard PCI or HA-PCI treatment at a dose of 2.
Table 1 Treatment plan for all patients receiving HA-PCI treatment
From April 2013 to March 2018, a total of 168 patients were randomly enrolled in this study.
p
There were no significant differences between the two groups in performance on other cognitive tests such as tests of memory, executive function, attention, motor function, and processing speed.
p
In summary, the results of this study show that compared with traditional PCI, the probability of neurocognitive decline in patients with small cell lung cancer receiving HA-PCI has not been found to be reduced.
Belderbos, José SA et al.
Belderbos, José SA et al.
Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
Journal of Thoracic Oncology, Volume 16, Issue 5, 840-849 Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
Leave a message here
